drugset / Trial / NCT00217022
Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis
Phase 2/3
Terminated
16 enrolled
Mayo Clinic
AstraZeneca · collabNational Center for Research Resources (NCRR) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Patients will receive budesonide or placebo for the treatment of active lymphocytic colitis. This study includes stool collections, blood draws, weekly questionnaires and a sigmoidoscopy. The study hypothesis is that budesonide will be safe and effective compared with placebo for the treatment of diarrhea in lymphocytic colitis.
Timeline
- Start
- 2003-06
- Primary completion
- 2008-02
- Completion
- 2008-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Budesonide | Small molecule | 9 mg | — |